一分钟看懂
这是一项关于肝细胞癌的早期 I 期研究，登记的药物或干预包括NK521 Cell Injection，当前状态为尚未开始招募。登记地点显示中国合肥有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
NK521 Cell Injection · 早期 I 期
登记条件中文摘要
年龄范围：18岁至65岁
登记的基本范围为不限性别，年龄18岁至65岁；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- 1st affiliated hospital of Anhui Medical University · 合肥
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Patients with pathologically confirmed relapsed/refractory advanced solid tumors, including hepatocellular carcinoma and ovarian cancer. Patients enrolled in the intraperitoneal perfusion group (Group B) must have malignant ascites with tumor cells identified in the ascitic fluid.
- * Patients with advanced solid tumors who have received ≥ 1 line of standard therapy.
- * At least one measurable lesion on CT or MRI per RECIST v1.1.
- * ECOG performance status 0-2.
- * Life expectancy ≥3 months.
- * Women of childbearing potential must be non-lactating with a negative serum pregnancy test within 1 week before enrollment; all subjects must agree to use contraception from signing informed consent until 6 months after the last NK521 infusion.
- * Able to comply with the study protocol and follow-up procedures.
- * Voluntarily signed and provided written informed consent.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07657416；登记信息更新于 2026-09-30；本站同步于 2026-10-08。